Citigroup’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-29,700
Closed -$935K – 5810
2022
Q2
$935K Buy
+29,700
New +$1.04M ﹤0.01% 2716
2021
Q4
– Sell
-74,900
Closed -$5.6M – 5808
2021
Q3
$5.6M Buy
74,900
+29,800
+66% +$2.5M ﹤0.01% 1744
2021
Q2
$4.17M Buy
45,100
+42,300
+1,511% +$3.6M ﹤0.01% 2055
2021
Q1
$248K Buy
+2,800
New +$278K ﹤0.01% 3899

Other funds holding ARKG

Citigroup's ARKG Position: Q3 2026 in Review

Citigroup reduced its ARK Genomic Revolution ETF (ARKG) stake by 68% in Q3 2026, selling an estimated $66.7M and leaving 689,700 shares worth $37.4M. The position accounts for 0.01% of the portfolio, ranked #885.

Citigroup first reported a position in ARKG in Q1 2018 and has held it in 35 quarters since. The position peaked at $91.4M in Q2 2026. 316 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.

  • Citigroup held 689,700 shares of ARK Genomic Revolution ETF worth $37.4M as of Q3 2026.
  • Citigroup sold 1,482,615 ARK Genomic Revolution ETF shares in Q3 2026, an estimated $66.7M.
  • ARK Genomic Revolution ETF made up 0.01% of Citigroup's portfolio in Q3 2026, its #885 holding.
  • Citigroup first reported a position in ARK Genomic Revolution ETF in Q1 2018 and has held it in 35 quarters since.
  • Citigroup's ARK Genomic Revolution ETF position peaked at $91.4M in Q2 2026.
  • 316 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.